Protalix's PRX-115 shows promising Phase 1 data for chronic refractory gout, with long-term urate reduction after a single dose, but faces significant competition and safety concerns. Protalix's ...
Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by Sobi.
SAN DIEGO, March 5, 2025 /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares ...
JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic ...
Swedish Orphan Biovitrum (OM:SOBI) has completed its acquisition of Arthrosi Therapeutics. The deal adds a late stage Phase 3 investigational therapy for gout to Sobi’s portfolio. The transaction ...
SAN DIEGO, Dec. 18, 2024 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 ...
— REDUCE 1 is a study running in parallel with REDUCE 2 to evaluate pozdeutinurad's efficacy in lowering serum urate (sUA) levels and resolution of target tophi in gout patients — SAN DIEGO, July 1, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results